Eli Lilly And Company v. Teva Parenteral Medicines, Inc.

by Robins Kaplan LLP

Case Name: Eli Lilly and Company  v. Teva Parenteral Medicines, Inc., Civ. No. 10-cv-01376-TWP-DKL, 2014 U.S. Dist. LEXIS 43885 (S.D. Ind. Mar. 31, 2014) (Walton-Pratt, J.)

Drug Product and Patent(s)-in-Suit: Alimta® (pemetrexed disodium); U.S. Pat. No. 7,772,209 (“the ’209 patent”)

Nature of the Case and Issue(s) Presented: The ’209 patent is a method-of-use patent that claims the co-administration of pemetrexed disodium with two nutrients—folic acid and vitamin B-12—to prevent side effects from the pemetrexed disodium. Defendants argued that the prior art disclosed co-administration, relying on a mouse study and a Phase I clinical study that modulated the toxicity of pemetrexed by administering folic acid. Defendants argued that these early studies would lead a person of skill in the art (“POSA”) to administer pemetrexed with folic acid. Defendants further argued that the prior art taught that nutritional issues contributed to pemetrexed toxicities and that a POSA would be motivated to combine vitamin B12 with folic acid based on the general knowledge regarding the association of elevated homocysteine with low levels of folic acid and vitamin B12. Defendants also argued that the dosing regimen was obvious in light of ranges disclosed in the prior art. The court was not persuaded by defendants’ arguments. It found that the folic-acid prior art was deficient because those early studies would not correlate to effectiveness in humans, and one reference actually taught away from the invention because it showed that folic acid decreased the effectiveness of pemetrexed. Moreover, the court found that the prior art did not disclose the claimed ranges since there was no confirmed correlation between the use of pemetrexed and folic acid and vitamin B-12. In addition, the court determined that there was evidence of skepticism in the art, failed attempts by others and unexpected properties that could serve as secondary considerations favoring non-obviousness.

Defendants also argued that the asserted claims were invalid for obviousness-type double patenting based on Eli Lilly’s expired ’974 patent. The ’974 patent claims a method of reducing toxicity of a GARFT inhibitor or other antifolate by treating a mammal with folic acid about 1 to 24 hours prior to administration of the antifolate. The court found the asserted claims patentably distinct because the ’974 patent does not disclose pemetrexed or contain any data regarding pemetrexed. Because of pemetrexed’s different toxicity, a POSA would not have selected it.

Defendants finally argued that the asserted claims were invalid under 35 U.S.C. § 112. Defendants asserted the patent failed to meet the written-description requirement, because “an effective amount of pemetrexed” with folic acid and vitamin B-12 pretreatment is insufficient since the specification does not give a particular dose of pemetrexed. The court found that the patent provided sufficient disclosure, since the specification discloses using a pretreatment regimen in combination with an “effective amount” of pemetrexed, not an amount of pemetrexed that would be effective if combined with the vitamin pretreatment. A POSA would be able to determine the effective amount of pemetrexed prior to adding the vitamin pretreatment and would combine it with the vitamin regime. Defendants also argued that the claims were not enabled. The court rejected this argument because the numerous prior-art references available at the time of filing provided data regarding the amount of pemetrexed capable of producing a therapeutic benefit. Thus, undue experimentation was not required to reach the effective amount of pemetrexed.

Why Eli Lilly Prevailed:  Eli Lilly prevailed because the prior art did not teach or suggest the combination of the pemetrexed and vitamin supplements. The prior art references disclosed early testing of pemetrexed and vitamin supplements. The court was not persuaded that a mouse study could provide sufficient teachings, because a POSA would have recognized the difficulty in translating a mouse study to human trials, since mouse models are poor predictors for antifolates’ toxicity. The court also found that the Phase I clinical trial taught away from the claimed invention, since folic acid negatively impacted the efficacy of pemetrexed. Oncologists were not concerned with the pemetrexed toxicities and, while the Phase I clinical trial reported lower toxicities, higher doses of pemetrexed were required. In addition, the court found that the addition of vitamin B-12 would counteract the antifolate and reduce the efficacy of pemetrexed. The court also found secondary considerations favoring non-obviousness, since the FDA was skeptical about the invention and consistently rejected the vitamin supplementation protocol; others had tried and failed with vitamin supplementation; and the results were unexpected since the vitamin supplementation increased the effectiveness of pemetrexed.



DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.